Salix Reaches New 52-Week High (SLXP)

NEW YORK ( TheStreet) -- Salix Pharmaceuticals (Nasdaq: SLXP) hit a new 52-week high Tuesday as it is currently trading at $54.53, above its previous 52-week high of $53.99 with 24,681 shares traded as of 9:40 a.m. ET. Average volume has been 756,600 shares over the past 30 days.

Salix has a market cap of $3.03 billion and is part of the health care sector and drugs industry. Shares are up 9.1% year to date as of the close of trading on Monday.

Salix Pharmaceuticals, Ltd. acquires, develops, and markets prescription drugs and medical devices used in the treatment of various gastrointestinal diseases in the United States. The company has a P/E ratio of 33.5, above the average drugs industry P/E ratio of 33.2 and above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Salix as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth, compelling growth in net income, notable return on equity and solid stock price performance. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. You can view the full Salix Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing